15 Protocols · 100% Generic INN

Reference Source:

Launch in App

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

ICD-10: L51.2Source: Fitzpatrick's Dermatology - Ch. 44

History & Clinical Examination Pearls

  • •Drug latency & high-risk culprits: Onset occurs 1 to 4 weeks after initiation of high-risk medication (allopurinol, carbamazepine, lamotrigine, phenytoin, sulfamethoxazole-trimethoprim, nevirapine, or oxicam NSAIDs)
  • •Prodromal constitutional symptoms: High spiking fever, stinging eye pain, photophobia, sore throat, painful swallowing, cough, and generalized arthralgias preceding cutaneous eruption by 1 to 3 days
  • •Cutaneous detachment extent: SJS involves < 10% body surface area (BSA) epidermal detachment; SJS/TEN overlap involves 10-30% BSA; TEN involves > 30% BSA detachment with massive transdermal fluid and heat loss
  • •Skin tenderness & atypical target lesions: Ill-defined, coalescing, dusky purpuric macules with dark necrotic centers and atypical targetoid morphology, starting symmetrically on trunk and face with exquisite cutaneous pain
  • •Nikolsky sign & Asboe-Hansen sign: Positive Nikolsky sign (shearing force dislodges epidermis from dermis) and positive Asboe-Hansen sign (lateral extension of flaccid bulla on downward pressure)
  • •Severe mucosal erosion (>= 2 surfaces): Painful hemorrhagic crusting and ulceration of vermilion lip border, oral cavity, bilateral purulent or pseudomembranous conjunctivitis, and genital/perianal mucosal denudation

Diagnostic Tests & Paraclinics

  • •Urgent Frozen Section Skin Biopsy: Diagnostic punch or shave biopsy demonstrating full-thickness epidermal necrosis, basal vacuolar degeneration, subepidermal blister cleavage, and sparse dermal lymphocytic infiltrate (sparing deep dermis)
  • •SCORTEN Severity-of-Illness Score: Calculate within 24 hours of admission based on 7 variables: age >= 40, heart rate >= 120, active malignancy, epidermal detachment > 10%, serum urea > 10 mmol/L, serum glucose > 14 mmol/L, serum bicarbonate < 20 mmol/L (SCORTEN >= 5 predicts > 90% mortality)
  • •Laboratory panel: CBC (marked leukopenia, neutropenia indicates grave prognosis), comprehensive metabolic panel, arterial blood gas, blood and denuded skin surface bacterial cultures

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Enteral high-calorie high-protein nutrition via nasogastric tube (25-30 kcal/kg/day, 1.5-2 g/kg/day protein); strict transfer to dedicated Burn Intensive Care Unit; warm ambient room temperature (30-32°C) to prevent hypothermia
  • ✓Monitoring: Continuous vital signs, hourly urine output via Foley catheter (target 0.5-1 mL/kg/hr), daily strict fluid balance, serial photographic mapping of detached body surface area, daily ophthalmology slit-lamp examination to prevent symblepharon and corneal perforation
  • ✓IV Hydration: Intravenous crystalloid volume resuscitation with Lactated Ringer's using modified Parkland/Consensus protocol: 2 mL/kg/% BSA detachment over 24 hours (half in first 8 hours), titrated to urine output and hemodynamic stability
  • ✓Pharmacotherapy (Generic Only): IMMEDIATE CESSATION OF ALL SUSPECTED CAUSATIVE DRUGS; SYSTEMIC IMMUNOMODULATION: Cyclosporine 3-5 mg/kg/day IV divided every 12 hours for 10-14 days (halts fas-ligand mediated apoptosis) OR Intravenous Immunoglobulin (IVIG) 1 g/kg/day IV for 3 consecutive days (total 3 g/kg); OPHTHALMIC CARE: Preservative-free artificial tears every 1 hour PLUS Moxifloxacin 0.5% ophthalmic drops every 4 hours PLUS topical Dexamethasone 0.1% drops twice daily under ophthalmology guidance; daily glass rod lysis of conjunctival adhesions; TOPICAL CUTANEOUS CARE: Non-adherent silicone or petroleum jelly-impregnated dressings; topical silver sulfadiazine is strictly avoided (contains sulfonamide); chlorhexidine 0.05% baths; ANALGESIA: Fentanyl 25-50 mcg IV or Morphine 2-5 mg IV titrated

Red Flags & Clinical Pitfalls

  • !Delaying the immediate withdrawal of the offending drug, which directly correlates with exponentially increased mortality
  • !Failing to perform daily ophthalmologic exams with sweep of fornices, leading to cicatricial symblepharon, trichiasis, corneal ulceration, and permanent blindness
  • !Administering silver sulfadiazine or other sulfa-containing topical agents in a patient with sulfa-induced toxic epidermal necrolysis

Extensive Mucocutaneous Pemphigus Vulgaris

ICD-10: L10.0Source: Fitzpatrick's Dermatology - Ch. 57

History & Clinical Examination Pearls

  • •Initial mucosal erosion prodrome: Painful, non-healing oral ulcers and erosions of the buccal mucosa, gingiva, and soft palate preceding cutaneous blisters by months; severe dysphagia, odynophagia, and weight loss
  • •Fragile cutaneous flaccid blisters: Progressive emergence of thin-walled, extremely fragile, flaccid bullae on normal-appearing or erythematous skin that rupture effortlessly leaving raw, painful, bleeding erosions
  • •Autoimmune pathogenesis: IgG autoantibodies targeting desmoglein 3 (mucosal-dominant) and desmoglein 1 (mucocutaneous) leading to loss of keratinocyte intercellular adhesion (acantholysis)
  • •Flaccid bullae & vegetative erosions: Easily ruptured, shallow, weeping, painful erosions with irregular margins across the scalp, face, chest, axillae, groin, and back; lack of intact bullae due to mechanical fragility
  • •Positive Nikolsky sign: Direct pressure or lateral friction applied to normal-appearing perilesional skin produces epidermal peeling and denudation
  • •Mucosal involvement: Extensive erosions involving the oral cavity, hypopharynx, larynx (hoarseness), esophagus, conjunctiva, urethra, and anogenital mucosa

Diagnostic Tests & Paraclinics

  • •Direct Immunofluorescence (DIF - Gold Standard): Perilesional punch biopsy demonstrating intercellular IgG and C3 deposition in a lace-like or 'fishnet' lattice pattern throughout the epidermis
  • •Histopathological Examination: Routine H&E biopsy of intact vesicle edge showing intraepidermal supra-basal acantholytic clefting with intact basal cells attached to the basement membrane ('tombstone' appearance)
  • •Serum ELISA for Desmoglein: Quantitation of circulating anti-desmoglein 1 (anti-Dsg1) and anti-desmoglein 3 (anti-Dsg3) IgG titers (titer levels correlate with disease activity and mucosal/cutaneous extent)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: High-calorie soft or pureed diet with bland non-acidic foods; strict avoidance of crusty or spicy foods; bed rest with minimal friction; protect skin from shear stress
  • ✓Monitoring: Daily monitoring for secondary bacterial infection, daily body weight, blood pressure, blood glucose, strict fluid balance, assess oral intake
  • ✓IV Hydration: Intravenous 0.9% Normal Saline or Lactated Ringer's to replace transdermal exudative fluid loss if oral intake compromised by severe oropharyngeal erosions
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE SYSTEMIC IMMUNOSUPPRESSION: Prednisone 1 to 1.5 mg/kg/day orally (or Methylprednisolone 60-80 mg IV daily) PLUS Rituximab 1000 mg IV on days 1 and 15 (repeat every 6 months as maintenance; achieves rapid complete remission); ADJUVANT STEROID-SPARING AGENTS (if Rituximab unavailable): Azathioprine 2-2.5 mg/kg/day oral OR Mycophenolate Mofetil 2-3 g/day oral divided every 12 hours; TOPICAL & LOCAL CARE: Triamcinolone acetonide 0.1% dental paste for oral erosions; Nystatin oral suspension 500,000 units swish and swallow 4 times daily to prevent oral candidiasis; GASTROPROTECTION: Famotidine 20 mg oral twice daily; OSTEOPROPHYLAXIS: Calcium carbonate 1000 mg plus Vitamin D3 800 IU daily; INFECTION PROPHYLAXIS: Sulfamethoxazole-Trimethoprim single-strength daily for Pneumocystis jirovecii prophylaxis while on high-dose immunosuppression

Red Flags & Clinical Pitfalls

  • !Secondary cutaneous superinfection with Staphylococcus aureus or Streptococcus pyogenes leading to rapid fatal bacteremia and septic shock across denuded dermis
  • !Disseminated Kaposi varicelliform eruption (Eczema Herpeticum) due to Herpes Simplex Virus superimposed on pemphigus erosions
  • !Acute adrenal crisis following abrupt cessation or rapid tapering of prolonged high-dose systemic corticosteroid therapy

Generalized Bullous Pemphigoid

ICD-10: L12.0Source: Fitzpatrick's Dermatology - Ch. 58

History & Clinical Examination Pearls

  • •Elderly demographic & neurological association: Typically presents in elderly individuals (> 70 years); strong clinical association with neurodegenerative disorders (dementia, Parkinson disease, stroke, multiple sclerosis)
  • •Urticarial prodromal phase: Weeks to months of intense, intractable generalized pruritus and non-specific urticarial plaques or eczematous lesions preceding blister eruption
  • •Autoimmune pathogenesis: IgG autoantibodies targeting hemidesmosomal adhesion proteins BP180 (type XVII collagen) and BP230 in the epidermal basement membrane zone
  • •Tense subepidermal bullae: Tense, dome-shaped, thick-walled serous or hemorrhagic blisters measuring 1 to 5 cm arising on erythematous urticarial bases or normal skin (predominantly flexural aspects of limbs, lower abdomen, medial thighs)
  • •Negative Nikolsky sign: Lateral traction on perilesional skin does NOT dislodge the epidermis (blister cleavage is subepidermal, preserving epidermal structural integrity)
  • •Mucosal sparing: Oral and mucosal involvement is characteristically absent or mild (< 10-20% of cases), distinguishing bullous pemphigoid from pemphigus vulgaris

Diagnostic Tests & Paraclinics

  • •Direct Immunofluorescence (DIF): Biopsy of perilesional skin demonstrating intense continuous linear deposition of IgG and C3 along the basement membrane zone (dermal-epidermal junction)
  • •Histopathological Examination: Routine biopsy of an intact early small vesicle showing subepidermal blister cavity with an inflammatory infiltrate predominantly composed of eosinophils in the blister and upper dermis
  • •Serum ELISA for BP180 & BP230: High circulating titers of anti-BP180 (NC16A domain) and anti-BP230 antibodies (correlating with clinical disease activity); marked peripheral blood eosinophilia

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Regular high-protein, age-appropriate diet; gentle skincare with soft cotton clothing; fall prevention precautions in elderly patients
  • ✓Monitoring: Daily inspection for new blister emergence, blood pressure, fasting blood glucose (steroid-induced diabetes screening), bone density evaluation
  • ✓IV Hydration: Routine oral fluids; IV maintenance only if patient is dehydrated or has diminished oral intake
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE TOPICAL THERAPY (Preferred in elderly to minimize systemic mortality): Clobetasol Propionate 0.05% cream 20-30 g applied to entire body (excluding face) daily for 4 weeks, then tapered over 4 months (demonstrated superior survival compared to high-dose oral steroids); FIRST-LINE SYSTEMIC THERAPY (for extensive or refractory disease): Prednisone 0.5 to 0.75 mg/kg/day orally, tapered gradually over 6 to 9 months; STEROID-SPARING / MILD DISEASE REGIMEN: Doxycycline 100 mg oral twice daily PLUS Nicotinamide 500 mg oral three times daily; ADJUVANT IMMUNOSUPPRESSION: Methotrexate 10-15 mg oral once weekly (with Folic Acid 5 mg weekly) OR Azathioprine 1-2 mg/kg/day oral; PRURITUS RELIEF: Hydroxyzine 25 mg oral at bedtime; GASTROPROTECTION: Omeprazole 20 mg oral daily

Red Flags & Clinical Pitfalls

  • !Excessive systemic corticosteroid toxicity in elderly multimorbid patients, resulting in lethal hospital-acquired pneumonia, sepsis, perforated peptic ulcer, or glycemic decompensation
  • !Misdiagnosing the pre-bullous prodromal phase as simple scabies, urticaria, or dry skin pruritus, allowing unchecked progression to extensive blistering
  • !Abrupt withdrawal of systemic corticosteroids precipitating severe rebound erythroderma or fulminant bullous reactivation

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

ICD-10: L27.0Source: Fitzpatrick's Dermatology - Ch. 45

History & Clinical Examination Pearls

  • •Delayed prolonged latency: Symptoms emerge characteristically 2 to 8 weeks after starting the inciting medication (longer latency than typical drug exanthems); symptoms frequently persist or flare for weeks even after drug cessation
  • •High-risk culprit drugs: Aromatic antiepileptics (carbamazepine, phenytoin, phenobarbital), allopurinol, sulfonamides (sulfamethoxazole), dapsone, minocycline, vancomycin, and abacavir
  • •Constitutional prodrome: Persistent high fevers (> 38.5°C), malaise, sore throat, generalized lymphadenopathy, and progressive facial swelling
  • •Facial edema & morbilliform eruption: Marked periorbital and centrofacial edema (pathognomonic hallmark) with a confluent maculopapular, morbilliform, or exfoliative eruption starting on face and upper trunk and progressing to erythroderma
  • •Tender generalized lymphadenopathy: Palpable, enlarged, tender lymph nodes in at least two distinct anatomical sites (cervical, axillary, inguinal)
  • •Visceral involvement signs: Jaundice, right upper quadrant tenderness (acute hepatitis in 70-80%), tachycardia, shortness of breath (myocarditis, pneumonitis), oliguria, or pedal edema (interstitial nephritis)

Diagnostic Tests & Paraclinics

  • •Hematologic Profile: Marked absolute eosinophilia (eosinophil count >= 0.7 x 10^9/L or >= 10%) and atypical lymphocytosis (RegiSCAR criteria)
  • •Hepatic & Renal Function: Marked elevation of serum AST, ALT (> 2-3x upper limit of normal) indicating acute drug-induced hepatitis; elevated serum creatinine and blood urea nitrogen with microscopic hematuria/proteinuria (acute interstitial nephritis)
  • •Viral Reactivation & Cardiac Biomarkers: Frequent reactivation of Human Herpesvirus 6 (HHV-6 DNA PCR), EBV, or CMV; serum Troponin I and ECG to rule out fulminant hypersensitivity myocarditis

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Regular diet as tolerated; bed rest; inpatient admission to progressive care or intensive care unit if severe visceral involvement (hepatic failure, myocarditis, renal failure)
  • ✓Monitoring: Daily liver function tests, daily serum creatinine and electrolytes, continuous telemetry if elevated troponin or chest pain, daily complete blood count with differential
  • ✓IV Hydration: Intravenous 0.9% Normal Saline or Lactated Ringer's to maintain hydration, especially if fever and exfoliative dermatitis are extensive
  • ✓Pharmacotherapy (Generic Only): IMMEDIATE WITHDRAWAL OF ALL SUSPECTED MEDICATIONS; FIRST-LINE SYSTEMIC CORTICOSTEROIDS: Methylprednisolone 1 mg/kg/day IV (or Prednisone 1 mg/kg/day orally) for patients with severe visceral organ involvement (hepatitis, nephritis, myocarditis); taper VERY slowly over 2 to 3 months (rapid tapering precipitates catastrophic rebound flares); REFRACTORY VISCERAL ORGAN FAILURE: Cyclosporine 3-5 mg/kg/day oral/IV OR Intravenous Immunoglobulin (IVIG) 2 g/kg total dose over 5 days; TOPICAL THERAPY: Triamcinolone acetonide 0.1% ointment applied to body twice daily; PRURITUS RELIEF: Diphenhydramine 25-50 mg oral/IV or Hydroxyzine 25 mg oral every 8 hours PRN; GASTROPROTECTION: Famotidine 20 mg oral daily

Red Flags & Clinical Pitfalls

  • !Tapering systemic corticosteroids too rapidly (in less than 6-8 weeks), which predictably triggers severe rebound DRESS flare and fulminant hepatic necrosis
  • !Failing to screen for acute hypersensitivity myocarditis (check baseline ECG and Troponin in all patients), which can cause sudden lethal cardiogenic shock or dysrhythmias
  • !Re-challenging the patient with the offending medication or chemically related drugs, which can provoke immediate fatal anaphylactoid multi-organ collapse

Acute Generalized Exanthematous Pustulosis

ICD-10: L40.1Source: Fitzpatrick's Dermatology - Ch. 43

History & Clinical Examination Pearls

  • •Ultra-short drug latency: Sudden eruptive onset within 24 to 48 hours after starting the inciting medication (much faster than SJS/TEN or DRESS)
  • •High-risk antimicrobial culprits: Beta-lactam antibiotics (aminopenicillins, cephalosporins), macrolides (erythromycin, azithromycin), pristinamycin, quinolones, and diltiazem (antifungal terbinafine may take 1-3 weeks)
  • •Acute systemic onset: Sudden high-grade fever (> 38°C), chills, and burning discomfort of the skin preceding or accompanying the pustular eruption
  • •Non-follicular sterile micropustules: Hundreds of tiny (< 5 mm), sterile, non-follicular pustules arising on a diffuse, background of fiery edematous erythema
  • •Intertriginous predilection: Eruption characteristically begins in intertriginous flexures (groin, axillae, submammary, neck folds) before rapidly generalizing to the trunk and limbs within hours
  • •Post-pustular desquamation: Pustules typically resolve spontaneously within 7 to 14 days, followed by widespread characteristic 'collarette' or pin-point desquamation

Diagnostic Tests & Paraclinics

  • •Hematologic Profile: Marked peripheral leukocytosis (WBC > 10,000/uL, often > 15,000/uL) with pronounced absolute neutrophilia (> 7,000/uL); mild transient eosinophilia in 30% of cases
  • •Histopathological Biopsy: Punch biopsy showing subcorneal or intraepidermal spongiform pustules filled with neutrophils, prominent dermal edema, and a mixed perivascular infiltrate of neutrophils and eosinophils
  • •Pustule Gram Stain & Culture: Gram stain and bacterial culture of unroofed pustule fluid are strictly STERILE (distinguishes AGEP from pustular bacteremia, folliculitis, or impetigo)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Regular oral diet; bed rest in a quiet, temperature-controlled environment; avoid skin friction and shear forces
  • ✓Monitoring: Vital signs every 4 hours, monitor body temperature, daily CBC with differential, check serum electrolytes and renal function until pustules resolve
  • ✓IV Hydration: Intravenous maintenance with 0.9% Normal Saline or Lactated Ringer's at 100 mL/hr if high fevers or decreased oral intake produce dehydration
  • ✓Pharmacotherapy (Generic Only): IMMEDIATE DISCONTINUATION OF OFFENDING MEDICATION (crucial step; produces rapid clinical resolution within 7-10 days); SYMPTOMATIC TOPICAL THERAPY: Betamethasone dipropionate 0.05% lotion or Hydrocortisone 2.5% cream applied to erythematous intertriginous areas twice daily during acute inflammatory phase; COOL COMPRESSES: Sterile saline or aluminum acetate wet compresses applied to burning flexural surfaces for 15-20 minutes 3 times daily; ANTIPYRETIC & ANALGESIC: Paracetamol 1000 mg oral/IV every 6 hours PRN (avoid NSAIDs); PRURITUS RELIEF: Cetirizine 10 mg oral daily PLUS Hydroxyzine 25 mg oral at bedtime; SYSTEMIC CORTICOSTEROIDS: Generally NOT required; brief course of Prednisone 0.5 mg/kg/day oral for 3-5 days only if severe generalized distress or organ involvement

Red Flags & Clinical Pitfalls

  • !Misdiagnosing AGEP as generalized pustular psoriasis of von Zumbusch, leading to unnecessary long-term toxic immunosuppressants (AGEP self-resolves promptly after drug withdrawal)
  • !Treating sterile pustules with empiric courses of additional broad-spectrum antibiotics, which can worsen or prolong the drug hypersensitivity reaction
  • !Severe dehydration and electrolyte imbalance in frail elderly patients during the acute exfoliative phase

Acute Erythrodermic Psoriasis Flare

ICD-10: L40.8Source: Fitzpatrick's Dermatology - Ch. 28

History & Clinical Examination Pearls

  • •Precipitating triggers: Abrupt withdrawal of systemic corticosteroids or potent topical steroids (rebound phenomenon), systemic infection (streptococcal, viral), hypocalcemia, or use of antimalarials/lithium in a patient with chronic plaque psoriasis
  • •Constitutional decompensation: Generalized shivering, severe hypothermia, rigors, malaise, insomnia, and intense burning skin pain across the entire body
  • •Metabolic & vascular collapse risk: Massive cutaneous vasodilation leading to high-output cardiac failure, high transdermal fluid loss (evaporative water loss), and massive protein depletion from exfoliative scaling
  • •Generalized confluent erythroderma: Fiery, bright red, confluent inflammatory erythema and scaling involving > 90% of the total body surface area (BSA)
  • •Exfoliative scaling & palmoplantar keratoderma: Fine bran-like or large sheet-like lamellar desquamation; severe palmoplantar keratoderma with painful fissures; dystrophic nails with subungual hyperkeratosis and onycholysis
  • •Hemodynamic & peripheral signs: Resting tachycardia, wide pulse pressure, peripheral pitting edema of lower extremities, generalized lymphadenopathy (dermatopathic lymphadenitis), and hypothermia (or paradoxical hyperthermia)

Diagnostic Tests & Paraclinics

  • •Serum Chemistry & Metabolic Panel: Marked hypoalbuminemia (< 2.5-3 g/dL due to exfoliative protein loss and catabolism); electrolyte derangements; elevated BUN/Creatinine (prerenal azotemia); check serum ionized calcium
  • •Hematologic Profile & Inflammatory Markers: Leukocytosis with marked left shift; normocytic normochromic anemia of chronic disease; markedly elevated ESR and CRP
  • •Cardiac Assessment: ECG (sinus tachycardia, ischemic strain) and Chest X-ray/Echocardiogram ruling out high-output congestive heart failure

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: High-calorie, high-protein diet (1.5-2 g/kg/day protein) to compensate for massive epidermal exfoliation; admission to dedicated dermatology or intensive care unit; ambient room warming (28-30°C) with heated blankets to prevent hypothermia
  • ✓Monitoring: Continuous core body temperature monitoring, continuous pulse oximetry, blood pressure every 2-4 hours, daily body weight, strict fluid input/output monitoring (target urine output > 0.5 mL/kg/hr)
  • ✓IV Hydration: Balanced intravenous crystalloid resuscitation (Lactated Ringer's or 0.9% Normal Saline at 150-200 mL/hr) titrated to replace substantial transepidermal evaporative losses and correct hypovolemia
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE FAST-ACTING SYSTEMIC RESCUE: Cyclosporine 3 to 5 mg/kg/day orally divided into two doses (provides rapid anti-inflammatory control within 48-72 hours) OR Infliximab 5 mg/kg IV infusion at weeks 0, 2, and 6; AVOID SYSTEMIC CORTICOSTEROIDS (high risk of fatal rebound pustular eruption upon withdrawal); SECOND-LINE AGENTS (for maintenance once stabilized): Acitretin 25-50 mg oral daily OR Methotrexate 10-15 mg oral/subcutaneous weekly (with Folic Acid 5 mg weekly); TOPICAL SOOTHING REGIMEN: Copious bland white petrolatum or bland emollient applied under warm, wet compresses 3-4 times daily; mid-potency topical steroids (Triamcinolone acetonide 0.1% ointment) applied sparingly; PRURITUS RELIEF: Hydroxyzine 25-50 mg oral every 8 hours; THROMBOPROPHYLAXIS: Enoxaparin 40 mg subcutaneous once daily (high VTE risk)

Red Flags & Clinical Pitfalls

  • !Administering systemic corticosteroids (e.g., Prednisone or Dexamethasone), which triggers catastrophic rebound generalized pustular psoriasis (von Zumbusch) upon tapering
  • !Failing to recognize high-output congestive heart failure and hypothermia resulting from massive cutaneous capillary shunting
  • !Severe secondary cutaneous bacterial infection progressing to Staphylococcus aureus or Streptococcus pyogenes septic shock

Severe Necrotizing Erysipelas and Complicated Cellulitis

ICD-10: A46Source: Fitzpatrick's Dermatology - Ch. 182

History & Clinical Examination Pearls

  • •Sudden explosive onset: Acute abrupt development over hours of high fever (39-40°C), shaking chills, and rapidly spreading localized skin redness and edema, typically on lower extremity or face
  • •Portals of bacterial entry: Pre-existing tinea pedis, interdigital maceration, venous stasis ulcer, surgical wound, saphenous vein harvest site, or insect bite allowing Group A Streptococcus (Streptococcus pyogenes) penetration
  • •Severe underlying predispositions: Chronic lymphedema (massive recurrence risk), morbid obesity, diabetes mellitus, prior episodes of cellulitis, and immunosuppression
  • •Sharply demarcated advancing border: Fiery red, hot, exquisitely tender plaque with a distinctly elevated, sharply demarcated margin separating affected skin from normal tissue (distinguishing erysipelas from deeper cellulitis)
  • •Peau d'orange & hemorrhagic bullae: Prominent dermal lymphatic obstruction causing cutaneous pitted edema resembling an orange peel (peau d'orange); development of dusky hemorrhagic bullae or superficial skin necrosis
  • •Systemic toxicity & lymphangitis: Linear erythematous streaking (lymphangitis) extending toward regional lymph nodes (tender lymphadenopathy); systemic hypotension, tachycardia, and altered sensorium signaling invasive toxic shock

Diagnostic Tests & Paraclinics

  • •Inflammatory Biomarkers: Marked leukocytosis (WBC > 15,000-20,000/uL) with profound left shift; massive elevation of serum C-reactive protein (CRP > 100-200 mg/L) and ESR
  • •Microbiology Panel: Two sets of peripheral blood cultures (positive in 5-10% of uncomplicated, but > 30% in bullous/necrotizing cases); wound swab or blister fluid Gram stain and culture; antistreptolysin O (ASO) and anti-DNase B titers
  • •Extremity Duplex Ultrasonography / MRI: Compression Doppler ultrasound to exclude concurrent deep venous thrombosis (DVT); MRI if necrotizing fasciitis is suspected (evaluates deep fascial fluid, gas, or fascial enhancement defect)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: NPO initially if systemic toxicity or surgical evaluation required; strict elevation of the affected extremity above the level of the heart to facilitate lymphatic drainage and accelerate edema resolution
  • ✓Monitoring: Vital signs every 2-4 hours, continuous pulse oximetry, mark the advancing erythematous border with a surgical marker pen every 6-8 hours to objectively track clinical progression
  • ✓IV Hydration: Intravenous crystalloid volume resuscitation with Lactated Ringer's or 0.9% Normal Saline at 150-200 mL/hr to treat dehydration and counteract inflammatory vasodilation
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE INTRAVENOUS ANTIMICROBIALS: Cefazolin 2 g IV every 8 hours OR Ceftriaxone 2 g IV every 24 hours OR Penicillin G 2 to 4 million units IV every 4 hours; IF MRSA RISK OR SEVERE TOXICITY: Vancomycin 15-20 mg/kg IV every 12 hours (target trough 15-20 mcg/mL) PLUS Clindamycin 600-900 mg IV every 8 hours (potent toxin-suppressing protein synthesis inhibitor for streptococcal toxic shock syndrome); ANALGESIA: Paracetamol 1000 mg IV every 6 hours PLUS Tramadol 50 mg IV PRN; COOL SALINE DRESSINGS: Sterile normal saline compresses applied to bullous/crusted areas for 20 minutes 3 times daily; THROMBOPROPHYLAXIS: Enoxaparin 40 mg subcutaneous once daily; SURGICAL EVALUATION: Immediate surgical consultation for exploration and debridement if bullae become hemorrhagic, skin becomes anesthetic, or fascial planes are involved

Red Flags & Clinical Pitfalls

  • !Failing to distinguish severe erysipelas from early necrotizing fasciitis (severe pain out of proportion to exam, skin anesthesia, wooden hardness, subcutaneous crepitus, or gas on imaging require emergency surgical fasciotomy)
  • !Neglecting to treat interdigital fungal tinea pedis, resulting in chronic repetitive erysipelas recurrences and irreversible elephantiasis nostras verrucosa lymphedema
  • !Rapid development of streptococcal toxic shock syndrome characterized by sudden profound hypotension and multi-organ failure

Eczema Herpeticum (Kaposi Varicelliform Eruption)

ICD-10: B00.0Source: Fitzpatrick's Dermatology - Ch. 195

History & Clinical Examination Pearls

  • •Pre-existing barrier dysfunction: Acute dissemination of Herpes Simplex Virus (HSV-1 or HSV-2) in a patient with underlying atopic dermatitis, Darier disease, pemphigus, or severe burn injury
  • •Sudden explosive clustering: Rapid eruption of intensely painful, clustered vesicles and pustules that erupt within 24 to 48 hours over chronic eczema plaques, especially on the face, neck, and upper trunk
  • •Severe systemic illness: High spiking fevers (39-40°C), chills, severe malaise, anorexia, irritability, and painful regional lymphadenopathy
  • •Monomorphic umbilicated vesicles: Crops of uniform, monomorphic, dome-shaped vesicles with central dells or umbilications arising on erythematous atopic skin
  • •Punched-out 'cookie-cutter' erosions: Vesicles rapidly rupture leaving characteristic, scalloped, painful, punched-out erosions that coalesce and develop thick hemorrhagic crusts
  • •Periocular & facial predilection: Marked involvement of head, face, and periorbital tissues; inspect carefully for dendritic corneal ulcerations, blepharitis, and keratitis

Diagnostic Tests & Paraclinics

  • •Viral Diagnostics (PCR - Gold Standard): Swab of unroofed vesicle base for Herpes Simplex Virus DNA PCR (rapid, highly sensitive, differentiates HSV-1 from HSV-2 and VZV)
  • •Tzanck Smear: Rapid bedside cytologic evaluation demonstrating multinucleated giant cells and keratinocytes with nuclear molding and ballooning degeneration
  • •Bacterial Cultures: Swabs of exudative erosions for aerobic bacterial culture to rule out secondary bacterial superinfection (Staphylococcus aureus colonizes > 90% of atopic lesions)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: High-calorie oral diet with fluid support; contact isolation precautions to prevent nosocomial viral transmission; bed rest
  • ✓Monitoring: Vital signs every 4 hours, daily body temperature monitoring, urgent ophthalmology slit-lamp consultation for any periorbital or facial involvement to rule out herpes keratitis
  • ✓IV Hydration: Intravenous crystalloid maintenance with 0.9% Normal Saline or 5% Dextrose in 0.45% Saline at 100-150 mL/hr to prevent dehydration, especially in young children
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE INTRAVENOUS ANTIVIRAL THERAPY: Acyclovir 5 to 10 mg/kg IV every 8 hours (infused slowly over 1 hour to prevent crystal nephropathy) for 7 to 10 days until lesions crust; in mild stable outpatients: Valacyclovir 1000 mg orally 3 times daily; SECONDARY BACTERIAL SUPERINFECTION COVERAGE: Cefazolin 1-2 g IV every 8 hours OR Vancomycin 15-20 mg/kg IV every 12 hours (if MRSA risk); WITHHOLD TOPICAL CALCINEURIN INHIBITORS: Immediately suspend topical Tacrolimus and Pimecrolimus, and withhold potent topical steroids during the active viral dissemination phase; OPHTHALMIC CARE (if keratitis confirmed): Ganciclovir 0.15% ophthalmic gel 1 drop 5 times daily under ophthalmologist direction (NEVER use topical steroids in active epithelial keratitis); ANALGESIA: Paracetamol 15 mg/kg oral/IV every 6 hours PRN

Red Flags & Clinical Pitfalls

  • !Applying topical corticosteroids or topical calcineurin inhibitors (tacrolimus) to active lesions, which suppresses local innate antiviral immunity and causes catastrophic viral dissemination
  • !Missing HSV keratitis in periorbital eruptions, which can lead to permanent corneal scarring, neovascularization, and visual loss
  • !Overwhelming systemic viremia with multiorgan failure, viral encephalitis, or fatal secondary Staphylococcus aureus / Streptococcus bacteremic sepsis

Calciphylaxis (Calcific Uremic Arteriolopathy)

ICD-10: E83.59Source: Fitzpatrick's Dermatology - Ch. 165

History & Clinical Examination Pearls

  • •End-stage renal disease & metabolic triggers: Occurs predominantly in end-stage renal disease (ESRD) patients on chronic hemodialysis or peritoneal dialysis, or kidney transplant recipients with tertiary hyperparathyroidism
  • •Agonizing ischemic skin pain: Sudden onset of severe, excruciating, intractable pain out of proportion to early visible skin changes, characteristically in areas with high adipose tissue (thighs, abdomen, buttocks, breasts)
  • •Therapeutic risk exposures: Warfarin anticoagulation (inhibits vitamin K-dependent Matrix Gla protein which prevents vascular calcification), calcium-based phosphate binders, high-dose active vitamin D (calcitriol), diabetes mellitus, and systemic corticosteroids
  • •Livedo reticularis & violaceous plaques: Early lesions present as tender, mottled, indurated, violaceous livedo reticularis or purpuric subcutaneous plaques resembling cellulitis
  • •Central ischemic black necrosis: Rapid progression of plaques to stellate, angulated, bullous lesions with central black eschar formation, progressing to deep, non-healing, punched-out ischemic ulcers
  • •Peripheral pulses preserved: Distal pedal pulses (dorsalis pedis and posterior tibial) remain easily palpable despite proximal cutaneous gangrene (disease is microvascular arteriolopathy, not macrovascular occlusion)

Diagnostic Tests & Paraclinics

  • •Mineral Metabolism Panel: Markedly elevated Calcium-Phosphate product (> 55-70 mg2/dL2), elevated serum parathyroid hormone (PTH > 300-800 pg/mL), hyperphosphatemia, and alkaline phosphatase
  • •Deep Punch or Incisional Skin Biopsy: Deep wedge/punch biopsy extending into subcutaneous adipose tissue demonstrating medial calcification of small-to-medium dermal and subcutaneous arterioles, intimal hyperplasia, endovascular fibrosis, and microthrombi (von Kossa or alizarin red staining); biopsy must be weighed against non-healing ulcer risk
  • •Soft Tissue Radiography & Bone Scintigraphy: Mammography-technique soft tissue plain X-rays of thighs demonstrating characteristic net-like or branching vascular calcifications; Tc-99m bone scintigraphy shows intense non-skeletal subcutaneous tracer uptake

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Low-phosphorus, low-calcium renal diet; strict avoidance of any local skin trauma; gentle pressure-relief mattress; bed rest
  • ✓Monitoring: Pain severity scores every 2-4 hours, daily wound inspection for signs of secondary bacterial infection, weekly serum calcium, phosphate, and intact PTH
  • ✓IV Hydration: Strict fluid restriction per hemodialysis protocol; optimize dialysis prescription (increase hemodialysis frequency to 4-5 sessions/week using low-calcium dialysate bath [1.0-1.25 mmol/L])
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE INTRAVENOUS CHELATION: Sodium Thiosulfate 25 g IV (diluted in 100 mL 0.9% Normal Saline) infused over the last 30-60 minutes of each hemodialysis session 3 times weekly (potent antioxidant and calcium-chelator; titrate to reduce nausea and metabolic acidosis); IMMEDIATE WARFARIN CESSATION: Discontinue Warfarin immediately and transition to subcutaneous Low-Molecular-Weight Heparin or Unfractionated Heparin; PHOSPHATE BINDERS: Non-calcium, non-aluminum phosphate binders (Sevelamer carbonate 800-1600 mg oral 3 times daily with meals); PARATHYROID SUPPRESSION: Cinacalcet 30-60 mg oral daily (calcimimetic; suppresses PTH without elevating calcium or phosphate); ANALGESIA: Multimodal pain management including Fentanyl transdermal patch 25 mcg/hr or Morphine IV titrated; WOUND CARE: Gentle enzymatic debridement with sterile hydrogel dressings; avoid aggressive surgical debridement which worsens tissue necrosis; HYPERBARIC OXYGEN THERAPY: Adjunctive hyperbaric oxygen (2.0-2.5 atmospheres for 90 min daily) to promote granulation

Red Flags & Clinical Pitfalls

  • !Misdiagnosing calciphylaxis as simple bacterial cellulitis or stasis dermatitis and continuing Warfarin therapy, leading to fulminant necrotizing gangrene
  • !Performing aggressive wide surgical debridement on unvascularized calciphylaxis ulcers, converting small plaques into massive, fatal non-healing wounds
  • !Secondary sepsis and septic shock originating from polymicrobial infected necrotic ulcers (the leading cause of 1-year mortality > 50-80%)

Acute Meningococcemia and Purpura Fulminans

ICD-10: A39.2Source: Fitzpatrick's Dermatology - Ch. 186

History & Clinical Examination Pearls

  • •Hyperacute fulminant progression: Rapid evolution over a matter of hours from non-specific fever, headache, and myalgias to profound septic shock, obtundation, and disseminated intravascular coagulation
  • •Epidemiologic context: Young adults, military recruits, college students in dormitories, or travelers; Neisseria meningitidis transmission via respiratory droplets
  • •Severe limb & muscular pain: Severe leg and back pain, cold extremities, and intense shivering during the early bacteremic phase before overt rash appears
  • •Evolving petechial to purpuric rash: Initial sparse, non-pruritic, pink-purple macules and petechiae distributed across the trunk and extremities, rapidly coalescing into widespread, retiform, jagged purpuric patches
  • •Purpura fulminans & peripheral gangrene: Large, tender, ecchymotic, bullous, violaceous-black infarctions with gunmetal-gray centers, progressing to peripheral acral symmetrical gangrene of fingers and toes
  • •Distributive & septic shock signs: Profound arterial hypotension, marked tachycardia, cold clammy extremities, delayed capillary refill (> 4-5 seconds), and altered level of consciousness

Diagnostic Tests & Paraclinics

  • •Emergency Blood Cultures & Skin Biopsy: Two sets of peripheral blood cultures; bedside punch biopsy or scraping of purpuric skin lesion edge showing gram-negative diplococci inside polymorphonuclear leukocytes and within dermal microthrombi
  • •Coagulation Profile & Consumptive Coagulopathy: Severe Disseminated Intravascular Coagulation (DIC): profound thrombocytopenia (platelets < 50,000/uL), prolonged PT/INR (> 2.0) and aPTT, severely depleted plasma fibrinogen (< 100 mg/dL), and massively elevated D-dimer (> 20 mcg/mL)
  • •Laboratory panel: Severe metabolic lactic acidosis (serum lactate > 4-8 mmol/L), severe prerenal azotemia, acute hypoglycemia and hyponatremia/hyperkalemia indicating Waterhouse-Friderichsen syndrome (acute bilateral adrenal hemorrhage)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Strict NPO, immediate intensive care unit (ICU) admission, respiratory droplet isolation precautions for first 24 hours of effective antibiotic therapy
  • ✓Monitoring: Continuous arterial line invasive blood pressure, central venous catheter, continuous pulse oximetry, Foley catheter for strict hourly urine output, serial lactate every 2 hours
  • ✓IV Hydration: Immediate aggressive intravenous crystalloid volume resuscitation with balanced crystalloids (Lactated Ringer's or 0.9% Normal Saline) 30 mL/kg bolus in first hour, titrated to mean arterial pressure >= 65 mmHg
  • ✓Pharmacotherapy (Generic Only): IMMEDIATE EMPIRIC ANTIMICROBIALS (within 30 minutes; do NOT delay for imaging or lumbar puncture): Ceftriaxone 2 g IV every 12 hours (pediatric: 100 mg/kg/day divided every 12 hours) OR Cefotaxime 2 g IV every 6 hours (or Penicillin G 4 million units IV every 4 hours if susceptible; Chloramphenicol 25 mg/kg IV every 6 hours if severe beta-lactam anaphylaxis); VASOPRESSOR INFUSION: Norepinephrine continuous IV infusion starting at 0.05-0.1 mcg/kg/min titrated to MAP >= 65 mmHg; add Vasopressin at 0.03 units/min if high-dose norepinephrine required; STEROID REPLACEMENT (for Waterhouse-Friderichsen adrenal crisis): Hydrocortisone 100 mg IV every 8 hours; DIC BLOOD PRODUCT MANAGEMENT: Fresh Frozen Plasma 15 mL/kg, Platelets 1 pool if < 50,000/uL with active bleeding, Cryoprecipitate 1-2 pools to keep fibrinogen > 150 mg/dL; CLOSE CONTACT POST-EXPOSURE CHEMOPROPHYLAXIS: Rifampin 600 mg oral twice daily for 2 days OR Ciprofloxacin 500 mg oral single dose OR Ceftriaxone 250 mg IM single dose

Red Flags & Clinical Pitfalls

  • !Delaying the administration of intravenous antibiotics while waiting to perform a lumbar puncture or arrange neuroimaging, which increases mortality from < 10% to > 60%
  • !Failing to recognize acute bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome) manifesting as refractory vasopressor-resistant shock responsive to stress-dose Hydrocortisone
  • !Omitting post-exposure antibiotic chemoprophylaxis for close household and healthcare contacts with direct oral secretion exposure

Ulcerative Pyoderma Gangrenosum associated with IBD

ICD-10: L88Source: Fitzpatrick's Dermatology - Ch. 72

History & Clinical Examination Pearls

  • •Systemic inflammatory association: Strongly associated with inflammatory bowel disease (ulcerative colitis > Crohn disease in 30-50% of cases), rheumatoid arthritis, seronegative spondyloarthropathies, or hematologic malignancies (MGUS, AML)
  • •Pathergy phenomenon (pathognomonic history): Onset or dramatic worsening of cutaneous ulcers triggered by minor trauma, surgical incisions, biopsy, debridement, or venipuncture (pathergy in 30-50%)
  • •Agonizing rapid ulceration: Begins as a tender, inflammatory pustule, erythematous nodule, or hemorrhagic bulla that rapidly breaks down and expands centrifugally into a deep, painful, necrotic ulcer over days
  • •Characteristic ulcer architecture: Deep, necrotizing ulceration with an overhanging, violaceous, bluish, or dusky undermined inflammatory border surrounded by an intense erythematous halo
  • •Suppurative necrotic crater: Ulcer bed is filled with purulent, mucinous, gelatinous exudate and yellow-green necrotic slough with cribriform or sieve-like appearance
  • •Anatomical distribution: Predominantly affects the pretibial lower extremities (anterior shins), peristomal skin in IBD patients with ostomies, abdomen, and buttocks

Diagnostic Tests & Paraclinics

  • •Histopathological Biopsy: Punch biopsy from the active advancing violaceous border demonstrating massive, dense dermal neutrophilic infiltrate with abscess formation, leukocytoclasia, and secondary vascular damage without primary vasculitis
  • •Microbiology & Cultures: Routine bacterial, fungal, and mycobacterial cultures of ulcer exudate and tissue biopsy are STERILE (essential to exclude infectious mimickers: atypical mycobacteria, deep fungal infections, ecthyma gangrenosum)
  • •Systemic Workup: Screen for underlying disease: Colonoscopy with mucosal biopsies (ruling out occult IBD), serum protein electrophoresis (SPEP/UPEP for MGUS/myeloma), peripheral blood smear, rheumatoid factor, and anti-CCP

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: High-protein wound healing diet; bed rest with elevation of the affected lower extremity; strict prohibition of any surgical debridement or surgical skin trauma (pathergy precautions)
  • ✓Monitoring: Serial wound measurements and photography of the ulcer border, daily pain scoring, monitor for secondary wound infection
  • ✓IV Hydration: Routine oral hydration; IV fluids if high fever or severe IBD flare causes dehydration
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE SYSTEMIC IMMUNOSUPPRESSION: Methylprednisolone 0.5 to 1 mg/kg/day IV (or Prednisone 60-80 mg oral daily) with gradual taper over 2-3 months; BIOLOGIC TARGETED THERAPY (especially in IBD-associated PG): Infliximab 5 mg/kg IV infusion at weeks 0, 2, and 6 (induces rapid ulcer healing and controls underlying bowel inflammation) OR Adalimumab 160 mg subcutaneous initial dose, then 80 mg at week 2, then 40 mg weekly; SECOND-LINE IMMUNOSUPPRESSANT: Cyclosporine 3-5 mg/kg/day oral divided every 12 hours (excellent rapid response); TOPICAL / INTRA-LESIONAL THERAPY (for mild or localized ulcers): Tacrolimus 0.1% ointment applied to ulcer borders twice daily PLUS intra-lesional Triamcinolone acetonide (10 mg/mL) injected into the active violaceous margin; GENTLE NON-ADHERENT DRESSINGS: Absorbent foam or hydrogel dressings; ANALGESIA: Morphine 2-5 mg IV or Tramadol 50 mg oral PRN

Red Flags & Clinical Pitfalls

  • !Performing sharp surgical debridement on pyoderma gangrenosum ulcers under the mistaken assumption of bacterial necrotizing infection, triggering explosive pathergy and massive tissue loss
  • !Failing to evaluate for asymptomatic underlying inflammatory bowel disease or hematologic malignancies in patients presenting with pyoderma gangrenosum
  • !Missing deep fungal (sporotrichosis, blastomycosis) or atypical mycobacterial infections that clinically mimic pyoderma gangrenosum, causing fungal dissemination with high-dose steroids

Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)

ICD-10: L98.2Source: Fitzpatrick's Dermatology - Ch. 39

History & Clinical Examination Pearls

  • •Acute systemic onset: Sudden onset of high spiking fevers (> 38.5°C), profound fatigue, headache, generalized arthralgias, and episcleritis or conjunctivitis
  • •Preceding triggers & etiologies: Classical/idiopathic (preceded by upper respiratory or gastrointestinal infection in 50%); Malignancy-associated (acute myeloid leukemia, myelodysplastic syndrome); Drug-induced (granulocyte colony-stimulating factor [G-CSF], all-trans retinoic acid [ATRA], azathioprine)
  • •Rapid plaque eruption: Sudden appearance of tender, juicy, erythematous nodules and plaques on the face, neck, and upper extremities
  • •Pseudovesicular succulent plaques: Exquisitely tender, well-demarcated, juicy, edematous red-violaceous plaques and nodules with a mamillated or cobblestone surface; intense upper dermal edema gives a false impression of fluid vesicles ('pseudovesiculation')
  • •Anatomical distribution: Symmetrical distribution predominantly involving the face, neck, dorsal hands, forearms, and upper trunk
  • •Ocular and extracutaneous signs: Bilateral conjunctivitis, episcleritis, painful swollen joints (knee, wrist, ankle), and tenderness over long bones (sterile neutrophilic osteomyelitis)

Diagnostic Tests & Paraclinics

  • •Hematologic Profile: Marked peripheral leukocytosis (WBC > 10,000-20,000/uL) with prominent absolute neutrophilia (> 70% mature neutrophils); marked elevation of ESR (> 20-50 mm/hr) and CRP (> 50-100 mg/L)
  • •Diagnostic Skin Biopsy: Punch biopsy showing dense, nodular infiltrate of mature polymorphonuclear neutrophils in the upper and mid-dermis with prominent leukocytoclasia, marked papillary dermal edema, and absence of true leukocytoclastic vasculitis
  • •Oncologic Screening: Complete peripheral blood smear, bone marrow biopsy (if cytopenias, atypical cells, or refractory disease present, ruling out occult AML or MDS), serum protein electrophoresis, and age-appropriate cancer screening

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Regular oral diet; bed rest; quiet room environment during acute febrile phase
  • ✓Monitoring: Body temperature every 4 hours, daily CBC with differential, monitor for rapid resolution of skin lesions following corticosteroid initiation
  • ✓IV Hydration: Intravenous maintenance with 0.9% Normal Saline at 100 mL/hr if febrile dehydration is present
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE SYSTEMIC CORTICOSTEROIDS (Gold Standard): Prednisone 0.5 to 1 mg/kg/day orally (typically 40-60 mg/day) as a single morning dose; lesions and fever resolve dramatically within 24 to 72 hours; taper gradually over 4 to 6 weeks to prevent relapse; FIRST-LINE STEROID-SPARING ALTERNATIVES (if steroids contraindicated): Potassium Iodide saturated solution (SSKI) 300 mg oral 3 times daily OR Colchicine 0.5 mg oral 3 times daily OR Dapsone 100-150 mg oral daily (check baseline G6PD level); TOPICAL & INTRA-LESIONAL THERAPY (for mild or localized lesions): Clobetasol propionate 0.05% ointment twice daily OR intra-lesional Triamcinolone acetonide (5-10 mg/mL); GASTROPROTECTION: Famotidine 20 mg oral daily; ANALGESIA: Paracetamol 1000 mg oral every 6 hours PRN

Red Flags & Clinical Pitfalls

  • !Failing to investigate for an underlying hematologic malignancy (particularly Acute Myeloid Leukemia or Myelodysplastic Syndrome), especially in patients with severe cytopenias, bullous Sweet syndrome, or oral mucosal involvement
  • !Tapering systemic corticosteroids too rapidly (in less than 2-3 weeks), triggering rapid inflammatory rebound of fever and skin lesions
  • !Administering Dapsone without first checking glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, precipitating severe acute hemolytic anemia

Cutaneous Leukocytoclastic Vasculitis (Hypersensitivity Vasculitis)

ICD-10: L95.8Source: Fitzpatrick's Dermatology - Ch. 163

History & Clinical Examination Pearls

  • •Precipitating antigenic triggers: Onset 7 to 21 days following an inciting trigger: medication (penicillins, cephalosporins, sulfonamides, NSAIDs, allopurinol), bacterial or viral infection (streptococcal pharyngitis, hepatitis B/C), or underlying connective tissue disease (SLE, rheumatoid arthritis)
  • •Orthostatic symptom distribution: Eruption is characteristically provoked or worsened by dependent venous stasis, presenting after prolonged standing or walking
  • •Systemic review of systems: Screen for renal involvement (dark tea-colored urine, facial edema), gastrointestinal involvement (colicky abdominal pain, melena, hematochezia), musculoskeletal involvement (arthralgias of knees/ankles), and peripheral neuropathy (mononeuritis multiplex)
  • •Palpable purpura (hallmark sign): Non-blanching, elevated, palpable erythematous to violaceous papules and plaques measuring 2 to 10 mm in diameter (differentiates vasculitis from non-inflammatory macular purpura)
  • •Dependent anatomical distribution: Symmetrical lesions concentrated over gravity-dependent lower extremities (ankles, shins, calves) and buttocks, with sparing of the face and trunk
  • •Evolving lesion morphology: Papules may coalesce into plaques, with formation of necrotic vesicles, bullae, or superficial ulcerations in severe vasculitis

Diagnostic Tests & Paraclinics

  • •Diagnostic Skin Biopsy (Timing Critical): Punch biopsy of an early lesion (< 24-48 hours old) demonstrating transmural postcapillary venular inflammation, fibrinoid necrosis of blood vessel walls, endothelial cell swelling, and neutrophilic infiltration with leukocytoclasia (nuclear debris / 'nuclear dust')
  • •Direct Immunofluorescence (DIF): Biopsy of lesion < 24 hours old showing perivascular deposition of IgA (hallmark of IgA vasculitis / Henoch-Schonlein purpura), or IgG, IgM, and C3 (immune complex vasculitis)
  • •Systemic Organ Screening Panel: Urinalysis with microscopic examination for hematuria, proteinuria, and red cell casts (glomerulonephritis screening); serum creatinine and BUN; stool guaiac test for occult blood; serum complement levels (C3, C4, CH50); hepatitis B/C serologies, ANA, ANCA, and cryoglobulins

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Regular diet; strict bed rest and lower extremity elevation above heart level to reduce hydrostatic pressure and decrease vascular purpura; avoid prolonged standing; wear loose cotton clothing
  • ✓Monitoring: Daily urinalysis for microscopic hematuria and proteinuria, daily blood pressure, weekly serum creatinine, serial inspection of skin lesions for ulceration
  • ✓IV Hydration: Routine oral hydration; maintain euvolemia with IV 0.9% Normal Saline if severe glomerulonephritis or GI bleeding is present
  • ✓Pharmacotherapy (Generic Only): REMOVAL OF TRIGGER: Immediately discontinue any suspected offending drug and treat underlying infection; SYSTEMIC CORTICOSTEROIDS (indicated for severe cutaneous ulceration, systemic renal, or GI involvement): Prednisone 0.5 to 1 mg/kg/day orally for 2 to 4 weeks, then tapered gradually; STEROID-SPARING AGENTS (for chronic or recurrent cutaneous disease): Colchicine 0.5 to 0.6 mg oral twice daily OR Dapsone 50 to 100 mg oral daily (after normal G6PD confirmation); TOPICAL THERAPY: Triamcinolone acetonide 0.1% cream applied to legs twice daily; ANALGESIA: Paracetamol 1000 mg oral every 6 hours PRN; GASTROPROTECTION: Famotidine 20 mg oral daily

Red Flags & Clinical Pitfalls

  • !Missing occult glomerulonephritis by failing to perform serial urinalyses and serum creatinine tests, allowing progression to irreversible renal failure
  • !Missing severe gastrointestinal ischemia or intussusception (especially in IgA vasculitis) manifesting as severe abdominal pain and lower GI bleeding
  • !Biopsying an old lesion (> 48 hours), where neutrophils have been cleared and replaced by secondary lymphocytes, yielding an equivocal or misleading histologic diagnosis

Staphylococcal Scalded Skin Syndrome

ICD-10: L00Source: Fitzpatrick's Dermatology - Ch. 180

History & Clinical Examination Pearls

  • •Pediatric vulnerability: Predominantly affects neonates and infants < 5 years of age (due to immature renal clearance of circulating exotoxins and lack of neutralizing antibodies) or adults with severe renal failure or immunosuppression
  • •Toxigenic bacterial focus: Systemic dissemination of exfoliative toxins A and B (ETA, ETB) produced by Staphylococcus aureus (phage group II, types 71 and 55) originating from a distant focus (purulent conjunctivitis, otitis media, nasopharyngeal impetigo, or omphalitis)
  • •Prodrome & irritability: Irritability, extreme cutaneous tenderness ('child screams when held or touched'), low-grade fever, and malaise
  • •Tender scarlatiniform erythema: Generalized, tender, diffuse, blanching erythema with prominent accentuation in flexural skin creases (perioral, perinasal, axillae, groin, neck)
  • •Perioral radial fissuring (Sad Man Facies): Characteristic radial fissuring, crusting, and scaling around the mouth, nose, and eyes without active mucosal ulceration
  • •Flaccid blisters & positive Nikolsky sign: Superficial, flaccid, fragile bullae that rupture effortlessly leaving moist, red, glistening, scalded-appearing denuded dermis; positive Nikolsky sign elicited by gentle lateral pressure

Diagnostic Tests & Paraclinics

  • •Bacterial Cultures (Source Identification): Cultures of suspected primary source (conjunctiva, nasopharynx, umbilicus, external ear canal, blood); bullae fluid and denuded skin surfaces are characteristically STERILE because lesions are toxin-mediated (differentiates SSSS from bullous impetigo)
  • •Histopathological Frozen Section: Frozen section or routine biopsy of blister roof demonstrating ultra-superficial cleavage at the granular layer of the epidermis (subcorneal cleavage plane due to toxin cleavage of desmoglein 1; completely preserves full-thickness viable epidermis, distinguishing SSSS from full-thickness epidermal necrosis in TEN)
  • •Laboratory panel: CBC (mild-to-moderate leukocytosis with left shift), serum electrolytes and BUN/creatinine (monitoring dehydration from transepidermal water loss)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Breast milk or formula feeding with frequent hydration in infants; handle child with extreme gentleness on padded surfaces (minimal handling protocol); keep room warm (28-30°C) to prevent hypothermia
  • ✓Monitoring: Vital signs every 2-4 hours, core body temperature, strict fluid intake and urine output (weighing diapers), daily inspection for secondary cutaneous infection
  • ✓IV Hydration: Intravenous maintenance crystalloid with 5% Dextrose in 0.2% or 0.45% Saline at calculated pediatric maintenance rate (plus 20-30% replacement for increased evaporative loss)
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE INTRAVENOUS ANTIMICROBIALS: Cefazolin 50-100 mg/kg/day IV divided every 8 hours OR Nafcillin/Oxacillin 100-150 mg/kg/day IV divided every 6 hours; IF MRSA SUSPECTED OR PREVALENT: Vancomycin 40-60 mg/kg/day IV divided every 6 hours (target trough 15 mcg/mL) PLUS Clindamycin 30-40 mg/kg/day IV divided every 8 hours (inhibits bacterial protein synthesis and halts exfoliative toxin production); CONTRAINDICATION: SYSTEMIC CORTICOSTEROIDS ARE STRICTLY CONTRAINDICATED (impairs immune clearance of Staphylococci); TOPICAL SKIN CARE: Copious white petrolatum or mupirocin ointment applied gently to denuded areas; sterile non-adherent silicone dressings; ANALGESIA: Paracetamol 15 mg/kg oral/IV every 6 hours PRN

Red Flags & Clinical Pitfalls

  • !Misdiagnosing SSSS as Toxic Epidermal Necrolysis (TEN) and administering systemic corticosteroids, which impairs host staphylococcal defense and drastically increases mortality
  • !Treating denuded skin surfaces with silver sulfadiazine in young infants, risking systemic sulfonamide toxicity and kernicterus
  • !Failing to recognize profound dehydration, hypothermia, and electrolyte collapse caused by loss of the superficial epidermal stratum corneum barrier

Acute Hereditary Angioedema Crisis

ICD-10: D84.1Source: Fitzpatrick's Dermatology - Ch. 42

History & Clinical Examination Pearls

  • •Bradykinin-mediated episodes: Recurrent, episodic, non-pitting, non-pruritic subcutaneous and submucosal edema lasting 2 to 5 days without urticaria or wheals (bradykinin-driven, completely refractory to antihistamines, corticosteroids, and epinephrine)
  • •Precipitating triggers: Physical trauma, dental extraction, surgical manipulation of upper airway, emotional stress, infectious illness, or exposure to estrogens (oral contraceptives, hormone replacement) and ACE inhibitors
  • •Familial history & abdominal attacks: Autosomal dominant inheritance (SERPING1 gene mutation; Type I: low C1-INH level, 85%; Type II: dysfunctional C1-INH, 15%); severe recurrent attacks of excruciating colicky abdominal pain, nausea, and vomiting due to intestinal wall edema
  • •Laryngeal edema (fatal manifestation): Progressive hoarseness, sensation of throat fullness, difficulty swallowing, stridor, and acute upper airway obstruction (leading cause of death in untreated HAE)
  • •Non-pitting, non-erythematous swellings: Circumscribed, asymmetric, non-pitting, pale subcutaneous swelling involving face, lips, eyelids, extremities, or genitals without associated erythema
  • •Absolute absence of pruritus & urticaria: Complete absence of hives, welts, or itching (erythema marginatum serpiginous prodromal rash may occur in 40-50% of attacks, but is strictly non-pruritic)

Diagnostic Tests & Paraclinics

  • •Complement Diagnostic Triad: Serum C4 level (persistently low in > 95% of patients even between attacks, making it the ideal initial screening test); C1-esterase inhibitor protein level (quantitatively reduced in Type I); C1-esterase inhibitor functional activity assay (reduced in both Type I and Type II)
  • •Emergency Abdominal Ultrasonography / CT: Bedside ultrasound or CT during an acute abdominal attack demonstrating marked bowel wall thickening, target sign (mural edema), and transient ascites without mechanical obstruction
  • •Normal Inflammatory Markers: Normal WBC count, CRP, and ESR during acute abdominal attacks (distinguishes HAE intestinal attack from acute bacterial peritonitis or appendicitis)

Standard Inpatient Orders (100% Generic INN)

  • ✓Diet/Activity: Strict NPO during laryngeal or severe abdominal attacks; bed rest; immediate preparation for emergency airway management
  • ✓Monitoring: Continuous pulse oximetry, continuous ECG telemetry, vital signs every 15 minutes, serial fiberoptic nasopharyngolaryngoscopy to inspect vocal cords and supraglottic edema; immediate access to emergency cricothyrotomy kit at bedside
  • ✓IV Hydration: Intravenous crystalloid volume resuscitation with 0.9% Normal Saline or Lactated Ringer's at 150-200 mL/hr to replace severe third-space fluid loss during abdominal attacks
  • ✓Pharmacotherapy (Generic Only): FIRST-LINE TARGETED RESCUE THERAPIES (Administer immediately; conventional antihistamines, corticosteroids, and epinephrine are INEFFECTIVE): Human Plasma-Derived C1-Esterase Inhibitor Concentrate 20 units/kg IV push over 10-15 minutes (or 1000 units fixed dose) OR Icatibant (selective bradykinin B2-receptor antagonist) 30 mg subcutaneous injection into abdominal wall (may repeat after 6 hours, max 90 mg/24 hr); SECOND-LINE RESCUE (if specific agents unavailable): Fresh Frozen Plasma 2 to 4 units IV (contains C1-inhibitor, though theoretical risk of transient worsening from kininogen substrate); ANALGESIA: Morphine 2-5 mg IV or Fentanyl 50-100 mcg IV for severe abdominal colic; ANTIEMETIC: Ondansetron 4-8 mg IV every 8 hours PRN; LONG-TERM PROPHYLAXIS: Danazol 200 mg oral daily OR Tranexamic Acid 1 g oral 3 times daily (or regular C1-INH infusions); SHORT-TERM PRE-PROCEDURAL PROPHYLAXIS: C1-Inhibitor concentrate 1000 units IV 1 hour before dental/surgical procedures

Red Flags & Clinical Pitfalls

  • !Relying on Epinephrine, Corticosteroids, and Antihistamines for acute HAE attacks; they are biologically INEFFECTIVE against bradykinin-mediated angioedema and delay life-saving targeted therapies
  • !Attempting blind oral endotracheal intubation in progressive laryngeal edema, which causes laryngeal spasm and complete airway closure; prepare for awake fiberoptic intubation or emergency surgical cricothyrotomy
  • !Subjecting a patient with acute HAE abdominal attack to unnecessary exploratory laparotomy due to misdiagnosing intestinal angioedema as an acute surgical abdomen